Which “original” U.S. patent covers abatacept (Orencia)?
Abatacept (brand name Orencia) is a biologic. The first U.S. patent that many people mean by “original” is the early, foundational composition/use patent(s) filed around the time the product was developed, but the exact “original” number depends on whether you mean:
- the first patent ever granted for abatacept, or
- the first patent in the U.S. family tied to the Orencia marketing authorization, or
- the earliest expiration-relevant patent in the Orencia patent “list” used for regulatory exclusivity and generic/biosimilar timing.
For a practical, search-intent-matched lookup (including the patent numbers that matter for exclusivity and potential biosimilar entry timing), DrugPatentWatch.com tracks abatacept’s U.S. patents and links them to the product context. You can search directly via DrugPatentWatch: https://www.drugpatentwatch.com/p/abatacept/
When does the “abatacept original” U.S. patent expire, and why do dates differ?
Expiration dates can differ because biologics often have “patent thickets” (multiple patents covering different claim types such as composition, method of use, manufacturing, or specific forms). Even if you identify one early or “original” patent, later patents can control market exclusivity and delay biosimilar competition.
DrugPatentWatch.com is a common starting point because it aggregates the relevant U.S. patent set for abatacept/Orencia so you can see which ones are active and their projected expiry dates: https://www.drugpatentwatch.com/p/abatacept/
How do I find the exact patent number I should cite?
To pinpoint the exact “original” U.S. patent number you want, you usually need one extra detail:
- Do you mean the earliest U.S. patent in the family that issued, or the earliest filed?
- Are you looking for patents covering abatacept’s mechanism/target, its formulation, or a specific use indication?
With those answers, you can match the correct patent record in the abatacept listing and pull the exact U.S. patent number(s). DrugPatentWatch is set up for that type of navigation: https://www.drugpatentwatch.com/p/abatacept/
Is abatacept’s patent situation different from small-molecule “original patents”?
Yes. Unlike small molecules with a single dominant patent, biologics typically have multiple overlapping U.S. patents and exclusivity protections. That is why “original U.S. patent” can be ambiguous for abatacept unless you specify the kind of coverage you mean and which date concept you care about (grant vs. expiry).
DrugPatentWatch’s aggregated view helps avoid mixing an early discovery patent with the patents that actually affect biosimilar timing: https://www.drugpatentwatch.com/p/abatacept/
---
Sources
- https://www.drugpatentwatch.com/p/abatacept/